Salta alla navigazione principale
Salta alla ricerca
Salta al contenuto principale
Ordina per
Medicine and Dentistry
Hepatocellular Carcinoma
100%
Immune Checkpoint Inhibitor
55%
Overall Survival
47%
Immunotherapy
38%
COVID-19
37%
Malignant Neoplasm
35%
Transcatheter Arterial Chemoembolization
22%
Progression Free Survival
21%
Severe Acute Respiratory Syndrome Coronavirus 2
19%
Non Small Cell Lung Cancer
18%
Sequela
17%
Tumor
16%
Inflammation
16%
Lymphocyte
15%
Diseases
15%
Liver Cancer
15%
Sorafenib
14%
Biological Marker
14%
Chemotherapy
13%
Transitional Cell Carcinoma
12%
Atezolizumab
12%
Neutrophil
12%
Programmed Death-Ligand 1
10%
Cancer
10%
Human Immunodeficiency Virus
10%
Bevacizumab
10%
Infection
10%
Hazard Ratio
10%
Programmed Cell Death
9%
Programmed Death 1 Ligand 1
8%
Neoplasm
8%
Non-Small Cell Lung Cancer
8%
Systemic Therapy
8%
Albumin
7%
Serositis
7%
Cancer Treatment
6%
Cohort Analysis
6%
Cancer Staging
6%
Lung Cancer
6%
Omicron Coronavirus Variant
6%
Clinical Trial
6%
Cancer Therapy
6%
Adverse Event
6%
Bilirubin
5%
Antibiotics
5%
Oncology
5%
Patient Selection
5%
Breast Cancer
5%
Liver Transplantation
5%
Retrospective Study
5%
Keyphrases
Hepatocellular Carcinoma
74%
Immune Checkpoint Inhibitors
50%
Overall Survival
34%
COVID-19
29%
Patients with Cancer
24%
Atezolizumab
23%
Progression-free Survival
20%
Immune Checkpoint Therapy
17%
Sorafenib
13%
Advanced Hepatocellular Carcinoma
13%
Unresectable Hepatocellular Carcinoma (uHCC)
12%
Transarterial Chemoembolization
10%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
10%
Meta-analysis
9%
Hazard Ratio
9%
Non-small Cell Lung Cancer (NSCLC)
9%
Programmed Cell Death Protein 1 (PD-1)
9%
95% Confidence Interval
8%
Programmed Death-ligand 1 (PD-L1)
8%
Clinical Outcomes
8%
Advanced Urothelial Carcinoma
8%
Chemoimmunotherapy
8%
Neutrophil-to-lymphocyte Ratio
7%
Objective Response Rate
7%
Unvaccinated
7%
Cirrhosis
7%
Vaccinated Individuals
7%
SARS-CoV-2 Infection
6%
Hepatocellular Cancer
6%
SARS-CoV-2 Omicron
6%
Omicron BA.1
6%
Body Mass Index
6%
Concomitant Medications
5%
Lenvatinib
5%
Europe
5%
Inflammation
5%
Multivariable
5%
Tumor mutational Burden
5%
Survival Benefit
5%
Disease Control Rate
5%
Antibiotics
5%
Child-Pugh B
5%
Tolerability
5%
Chemotherapy
5%
Median Overall Survival
5%
Prognostic Biomarker
5%
Monotherapy
5%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
83%
Immune Checkpoint Inhibitor
44%
Immunotherapy
38%
Overall Survival
30%
Malignant Neoplasm
30%
Atezolizumab
27%
Bevacizumab
26%
Progression Free Survival
20%
Adverse Event
15%
Sorafenib
15%
Diseases
14%
Biological Marker
14%
Clinical Trial
10%
Non Small Cell Lung Cancer
9%
Chemotherapy Regimens
9%
Liver Cirrhosis
7%
Liver Cancer
7%
Antibiotics
7%
Neoplasm
7%
Lenvatinib
6%
Protein Tyrosine Kinase Inhibitor
6%
Placebo
6%
Pembrolizumab
6%
Antimicrobial Agent
5%
Tolerability
5%
